Scarica l'app Stockscreener
57.08
4.08%
-2.425
Dopo l'orario di chiusura:
56.79
-0.285
-0.50%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$59.50
Aprire:
$58.75
Volume 24 ore:
1.12M
Relative Volume:
0.67
Capitalizzazione di mercato:
$5.52B
Reddito:
$4.10M
Utile/perdita netta:
$-568.53M
Rapporto P/E:
-9.1882
EPS:
-6.2118
Flusso di cassa netto:
$-401.18M
1 W Prestazione:
+5.15%
1M Prestazione:
+22.64%
6M Prestazione:
+0.54%
1 anno Prestazione:
+5.07%
Intervallo 1D:
$56.62
$58.96
Intervallo di 1 settimana:
$51.80
$62.53
Portata 52W:
$44.12
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
57.08 | 5.62B | 4.10M | -568.53M | -401.18M | -6.2118 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | JP Morgan | Overweight |
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? - The Motley Fool
CRISPR Therapeutics Soars On Gene Therapy Breakout - TipRanks
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - The Motley Fool
Recursion, Novavax, Crispr Therapeutics Stocks Slip Premarket After Cancer Therapy RallyRecursion Phar - Benzinga
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 11.2%Time to Buy? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Why CRISPR Therapeutics Is Suddenly Back In Focus - TipRanks
CRISPR Therapeutics AG (CRSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRISPR Therapeutics (CRSP): Orbis-led investors disclose 5.6% ownership stake - Stock Titan
CRSP|CRISPR Therapeutics AG|Price:53.550|Chg%:-0.440 - TradingKey
Stronger Revenue and Narrower Loss Might Change The Case For Investing In CRISPR Therapeutics (CRSP) - Sahm
Bank of America Corp DE Decreases Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRSP Stock Climbs After-Hours As CRISPR Maps Busy Second-Half Pipeline After Upbeat Q2 - stocktwits.com
CRISPR Therapeutics (CRSP) Stock Looks Fairly Valued Despite Pipeline Promise - Sahm
CRISPR Therapeutics (CRSP) CFO Prasad Raju makes bona fide gift of 750 shares - Stock Titan
CRISPR Therapeutics AG (CRSP) Stock Forecasts - Yahoo! Finance Canada
CRISPR Therapeutics AG $CRSP Stock Position Raised by Quantinno Capital Management LP - MarketBeat
Crispr Therapeut (CRSP) Stock News & Updates - Stock Titan
CRISPR Therapeutics (CRSP) Earnings Drew Fresh Interest, Is The Stock Below Fair Value? - Sahm
CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Hold at Wall Street Zen - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock News Today - TradingKey
Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
HC Wainwright Has Positive Forecast for CRSP FY2026 Earnings - MarketBeat
California State Teachers Retirement System Increases Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Brave Asset Management Inc. Cuts Stake in CRISPR Therapeutics AG $CRSP - MarketBeat
Dimensional Fund Advisors LP Sells 412,889 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates - simplywall.st
Why CRISPR Therapeutics (CRSP) Is Up 11.6% After CASGEVY Expansion And Pipeline UpdatesAnd What's Next - webull.com
CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310 (NASDAQ:CRSP) - Seeking Alpha
Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Citi Raises Price Target for CRISPR Therapeutics (CRSP) Amid Str - GuruFocus
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates - finance.yahoo.com
CRISPR Therapeutics AG Stock 12‑Month Price Target Raised to $84.39, Implies 70% Upside - TradingView
CRISPR Therapeutics AG (CRSP) Stock Analysis: Exploring the 75% Potential Upside for Investors - DirectorsTalk Interviews
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss of $0.94 per Share - GuruFocus
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates - finance.yahoo.com
CRISPR Therapeutics AG reports results for the quarter ended June 30Earnings Summary - TradingView
CRISPR Therapeutics reports Q2 2026: CASGEVY revenue $76M, net loss $91.2M, cash $2.36B - TradingView
Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q2 Revenue $10.2M, vs. FactSet Est of $7.4M - marketscreener.com
CRISPR Therapeutics Reports Second Quarter 2026 Financial Results and Pipeline Updates - Quiver Quantitative
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance UK
CRISPR Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results, Beats Estimates By $0.26 EPS - MarketBeat
CRISPR Therapeutics (CRSP) Rebounded In Its Latest Session, Is It Still Well Below Fair Value? - Yahoo Finance
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? - The Motley Fool
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance UK
CRSP|CRISPR Therapeutics AG|Price:46.770|Chg%:+0.230 - TradingKey
BlackRock (CRSP holder) discloses 7.99M-share, 8.3% stake in CRISPR Therapeutics - Stock Titan
CRISPR Therapeutics AG (CRSP) Cash Flow - TradingKey
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):